An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases.
Teleanu DM, Niculescu AG, Lungu II, Radu CI, Vladâcenco O, Roza E, Costăchescu B, Grumezescu AM, Teleanu RI. · 2022
Read An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases. by Teleanu DM, Niculescu AG, Lungu II, Radu CI, Vladâcenco O, Roza E, Costăchescu B, Grumezescu AM, Teleanu RI. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9180653.txt.
Introduction
Teleanu and co-authors overview oxidative stress, neuroinflammation, and neurodegenerative diseases as linked processes. Oxidative stress means harm from excess reactive oxygen species. It has been tied to the start and progress of several brain disorders. Inflammation in the brain interacts with it closely.
The review covers Alzheimer's, Parkinson's, and Huntington's diseases, plus amyotrophic lateral sclerosis. For each, it sums up proof linking reactive oxygen to disease pathways. Stress and inflammation feed each other, the authors note. Antioxidants, both made by the body and taken in, are discussed as therapy options. Many mechanisms still need study before efficient therapies arrive. Readers get a joint view of two forces behind brain decline.
Catalog record
| CREATOR | Teleanu DM, Niculescu AG, Lungu II, Radu CI, Vladâcenco O, Roza E, Costăchescu B, Grumezescu AM, Teleanu RI. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 78 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases By Daniel Mihai Teleanu, Adelina-Gabriela Niculescu, Iulia Ioana Lungu, Crina Ioana Radu, Oana Vladâcenco, Eugenia Roza, Bogdan Costăchescu, Alexandru Mihai Grumezescu, Raluca Ioana Teleanu, Sara Franceschelli, Lorenza Speranza, Chiara D’Angelo Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms23115938 ABSTRACT Abstract Oxidative stress has been linked with a variety of diseases, being involved in the debut and/or progress of several neurodegenerative disorders. This review intends to summarize some of the findings that correlate the overproduction of reactive oxygen species with the pathophysiology of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. Oxidative stress was also noted to modify the inflammatory response. Even though oxidative stress and neuroinflammation are two totally different pathological events, they are linked and affect one another. Nonetheless, there are still several mechanisms that need to be understood regarding the onset and the progress of neurodegenerative diseases in order to develop efficient therapies. As antioxidants are a means to alter oxidative stress and slow down the symptoms of these neurodegenerative diseases, the most common antioxidants, enzymatic as well as non-enzymatic, have been mentioned in this paper as therapeutic options for the discussed disorders. Keywords: reactive oxidative species, neuroinflammation, neurodegenerative disease, antioxidants 1. INTRODUCTION Neurodegenerative diseases are among the dominant causes of disability and morbidity worldwide, receiving considerable attention due to their high impact on the aging society. These diseases are mainly based on constant deterioration in neuronal function, leading to brain atrophy. Among the most common known neurodegenerative diseases, the following are presented in this review: Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) [1,2,3,4,5]. It has been observed that even though different neurodegenerative diseases develop in diverse brain sites and exhibit distinct etiologies, they may act upon similar cellular and molecular processes. Even though there are increasing efforts toward developing appropriate therapies for neurodegenerative diseases, there is still a high demand for efficient agents with therapeutic effects; however, there are still many challenges to face. Even to this day, the exact pathway through which the cellular and molecular mechanisms are involved in the modulation of the evolution of these diseases is unclear. Moreover, the lack of effective biomarkers hinders the possibility of early diagnosis for the majority of these diseases. There is also a need for personalized treatment due to secondary effects, such as inflammation, resulting from the disease’s progression, but most importantly, there is an issue regarding biological barriers. Because the therapeutic agents need to reach the central nervous system (CNS), it is necessary to tailor appropriate vectors that can surpass the brain–blood barrier (BBB) [3,6]. A feature that has been noticed to be common to neurodegenerative diseases is oxidative stress (OS) resulting from the unregulated production of reactive oxygen species (ROS) [7,8]. ROS are known to be linked to several meaningful cellular mechanisms. When ROS are overproduced, they can generate the oxidative deterioration of molecules involved in the progress of aging and several disorders such as cancer and neurodegenerative and cardiovascular diseases. Moreover, ROS-enhanced production may shift the redox balance of the cell towards the oxidative state, leading to its dysfunction and even death. However, naturally, the body has several mechanisms that can counterbalance the outcomes of OS, such as antioxidants. These antioxidants can be either internally produced or provided externally; they are able to detect ROS and reduce the oxidation of the affected cellular molecules. Nonetheless, an impaired antioxidant system may equally contribute to disease pathogenesis [9,10]. In more detail, high oxygen consumption, low antioxidant levels, and low regenerative capacity were observed to induce oxidative damage susceptibility in brain tissues [7]. Therefore, there is a constant need for the development of new approaches that can support the neuroprotective molecules entering the brain, thus implementing more efficient treatments for the disorders of the CNS [11]. In this regard, this paper reviews the significance of oxidative stress in neurodegenerative disorders. There will be a focus on the links between neuroprotection and antioxidants, oxidative stress, neuroinflammation, and mitochondrial dysfunction, as well as the recent advancements in the field. 2. OXIDATIVE STRESS AND NEURODEGENERATIVE EVENTS 2.1. Reactive Oxygen Species Generated in the Brain There have been several studies performed in order to determine the role of ROS in the evolution of neurodegenerative diseases, and the results have been promising. Even though results have indicated that ROS do not represent a triggering factor in these diseases, they can probably aggravate disease progression due to oxidative damage as well as their interaction with mitochondria [1,12]. Due to its electron structure and its two unpaired electrons, oxygen is prone to radical formation. Therefore, when discussing ROS, they are cataloged as a class of reactive molecules derived from oxygen. This class’s members are known for having short-term life and high reactivity due to their remaining valence electrons. Several ROS can be formed due to the reduction of oxygen through electron addition (Figure 1). Amongst all the types of ROS, ·OH is considered to be the most reactive and the one that can induce a cytotoxic effect [13]. [Figure: Generally known reactive oxygen species (ROS). Adapted from [13].] Cellular reactive oxygen species are usually produced from exogenous and endogenous sources. The sources for ROS production exogenously include, for example, ionizing radiation, as well as pharmaceuticals that use ROS production as means of action. Moreover, ROS can also be produced as by-products due to the metabolism of environmental chemicals. On the other hand, the endogenous sources are either mitochondrial or non-mitochondrial ROS-developing enzymes [13,14]. ROS are the result of cellular respiration, a process in which an electron breaks away from the electron transport chain and attaches to oxygen, resulting in superoxide anions (O2−). The mitochondria take part in the formation of ROS- through the electron transport chain (ETC)-, and indeed around 2% of the oxygen consumed by it is used for this purpose. In normal, healthy cells, up to 90% of ROS are generated as explained. However, the rest are generated by different enzymes. As examples of the enzymes that take part in the production of ROS, the following can be mentioned: monoamine oxidase, dihydroorotate dehydrogenase, and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox) [13,15]. The above-mentioned ETC is composed of five complexes: Complex I—NADH dehydrogenase, Complex II—succinate dehydrogenase, Complex III—coenzyme Q-cytochrome c reductase, Complex IV—cytochrome C oxidase, and Complex V—adenosine triphosphate (ATP) synthase. The first three complexes are in charge of the production of superoxide anions. Apart from ROS production, Complex I is also responsible for enhancing electron transfers from NADH to coenzyme Q—during which there is another process taking place called proton translocation from the matrix to the intermembrane space. Among the three complexes, Complex II is the one that produces the lowest levels of superoxide anions, but it is also involved in the reduction of coenzyme Q. Complex III is responsible for the production of superoxide anions in the intermembrane space [13]. However, under pathological conditions or within different organs, these enzymes have different capacities for ROS generation. For example, even though Complex I is considered the main source for ROS production in the brain, this is not the case for the heart and lungs, where Complex III is the primary source. Moreover,